The medical journal Annals of Pharmacotherapy has published an article, “Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis”, which concludes that dipeptidyl peptidase-4 (DPP-4) inhibitors increase the risk of Crohn’s disease (CD). It goes on to point out that these DPP-4 inhibitor diabetes drugs, such as … [Read more...]
Certain Diabetes Drugs Like Januvia Associated With Bile Duct Cancer
The risk of developing bile duct cancer, also known as cholangiocarcinoma, is almost doubled for type 2 diabetics using one of the following diabetes medicines: Januvia (sitagliptin) Janumet (sitagliptin / metformin HCl) Onglyza (saxagliptin) Kombiglyze XR (saxagliptin and metformin) Qtern (dapagliflozin and saxagliptin) Nesina … [Read more...]
Current Number Of Lawsuits Filed In The Four Diabetes Drugs Federal Court MDL Cases
From the February 15, 2018 version of this document, “MDL Statistics Report – Distribution of Pending MDL Dockets by Actions Pending” (accessed 2/21/18), published by the United States Judicial Panel on Multidistrict Litigation (JPML), we get the current number of cases filed in each of the four federal court Multidistrict Litigation (MDL) cases … [Read more...]
Pancreatic Cancer Lawsuits Reinstated for Incretin-Based Diabetes Drugs
Background Among the several different types of therapies indicated for treating type 2 diabetes are increatin mimetics. The medications approved by the FDA that fall into this class of drugs are: Byetta (exenatide) Bydureon (exenatide) Januvia (sitagliptin) Janumet (sitagliptin) Victoza (liraglutide) Previous scientific … [Read more...]
Rhabdomyolysis May Be Linked To A New Class Of Oral Diabetes Medicines
A class of diabetes drugs referred to as dipeptidyl peptidase-4 inhibitors may be associated with rhabdomyolysis, a side effect which involves severe muscle damage. In more detail, rhabdomyolysis is the breakdown of muscle tissue that leads to the release of muscle fiber contents into the blood. These substances are harmful to the kidney and … [Read more...]
Type 2 Diabetes Drugs Linked to Severe Joint Pain
Health Canada recently warned about the risk of severe, debilitating joint pain as a result of taking type 2 diabetes medications called dipeptidylpeptidase-4 (DPP-4) inhibitors. This DPP-4 inhibitors class of drugs includes the following: Onglyza Kombiglyze XR Nesina Kazano Oseni Glyxambi Janumet (XR) Januvia … [Read more...]